Compound Deep Dive
BPC-157: What the Research Actually Shows
Research use / not medical advice
This article is for research purposes only. All compounds discussed are intended for laboratory research use by licensed researchers — not for human consumption. Nothing here is medical advice.
Introduction
BPC-157 has become one of the most studied peptides in the research community — and one of the most discussed. It appears in papers on wound healing, gut protection, tendon repair, and neuroprotection. It also appears in a lot of corners of the internet where the science gets stretched well beyond what the data actually supports.
This article does one thing: review what the peer-reviewed research on BPC-157 actually shows, where the evidence is strong, where it's preliminary, and what gaps still exist. No hype. No clinical claims. Just the literature.
What is BPC-157?
BPC-157 stands for Body Protection Compound 157. It is a synthetic pentadecapeptide — a sequence of 15 amino acids — derived from a protein found naturally in human gastric juice. Its amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (GEPPPGKPADDAGLV).
It was first isolated and studied by researchers at the University of Zagreb, Croatia, where much of the foundational work was conducted. The compound is considered stable in human gastric juice, which has driven research interest in its gastrointestinal applications.
- Molecular weight: 1419.55 Da
- CAS number: 137525-51-0
- Format in research supply: lyophilized powder, typically in 5mg vials
BPC-157 is not approved by the FDA or any major regulatory body for human use. It has no completed human clinical trials. All research to date has been conducted in animal models, primarily rodents.
Mechanisms of action: what the research proposes
1. Upregulation of growth hormone receptor expression
Studies suggest BPC-157 may increase the expression of growth hormone receptors in tendon fibroblasts. This is notable because growth hormone plays a central role in tissue repair and collagen synthesis. Chang et al. (2011) demonstrated upregulated GH receptor expression in tendon fibroblasts following BPC-157 exposure in vitro.
2. Angiogenesis promotion
Multiple studies have identified BPC-157's influence on the VEGF (Vascular Endothelial Growth Factor) pathway, which drives the formation of new blood vessels. New vasculature is essential to wound healing. Hsieh et al. (2017) observed enhanced angiogenesis and healing in rat corneal injury models.
3. Nitric oxide system modulation
Research has documented BPC-157's interaction with the nitric oxide (NO) pathway, which regulates blood vessel dilation, inflammation control, and gut barrier integrity. BPC-157 appears to modulate NO synthesis in ways that may protect endothelial tissue and reduce inflammation.
4. FAK-paxillin pathway activation
In tendon research specifically, BPC-157 has been shown to activate the FAK (Focal Adhesion Kinase)-paxillin pathway, involved in cell migration and adhesion — both critical to tissue repair.
Research areas: what the evidence shows
Gastrointestinal protection and healing
This is where BPC-157 research is most extensive. Studies in rodent models have documented accelerated healing of gastric ulcers (induced by ethanol, NSAIDs, stress), protection of the intestinal mucosa against NSAID damage, reduction of inflammatory bowel symptoms, and improvements in gut motility. A 2014 review by Sikiric et al. in the World Journal of Gastroenterology summarized consistent anti-ulcer effects across models. Evidence strength: strong in animal models; no human clinical data.
Tendon and ligament repair
The second most developed area, and arguably the most cited. Rodent studies — predominantly from the Zagreb group — have shown accelerated healing of transected Achilles tendons, improved recovery after MCL transection, and enhanced tendon-to-bone healing. Krivic et al. (2006) showed rats with transected Achilles tendons recovered faster with superior tensile strength versus controls. Evidence strength: consistent across rodent studies; mechanism partially elucidated; no human clinical data.
Muscle healing
Rat crush-injury and laceration models have shown accelerated muscle fiber regeneration, reduced fibrosis, and improved functional recovery. Evidence strength: promising in animal models; earlier stage than the tendon literature.
Neuroprotection and CNS research
More recent rodent work has examined neuroprotective effects after traumatic brain injury, counteraction of dopamine-system dysregulation, reduction of neuroinflammation markers, and brain-lesion recovery. The apparent interaction with dopaminergic pathways is a notable area of mechanistic novelty. Evidence strength: interesting and expanding; all animal-model data.
Anti-inflammatory effects
Across research areas, a consistent finding is reductions in inflammation markers — TNF-alpha, IL-6, and NF-κB pathway activity — in injury models. This is likely downstream of NO modulation and shows some cross-validation across model types.
What the research does NOT show
- No completed human clinical trials. Every finding above comes from in vitro or animal models. Translating rodent physiology to human outcomes is not straightforward.
- No established dosing for humans. Animal study doses cannot be reliably extrapolated without clinical pharmacokinetic data.
- No FDA approval. BPC-157 is not approved for any human use.
- Limited long-term safety data. Most rodent studies are acute or subacute; long-term effects are not well characterized.
BPC-157 compound profile summary
| Property | Detail |
|---|---|
| Type | Synthetic pentadecapeptide |
| Amino acids | 15 (GEPPPGKPADDAGLV) |
| Molecular weight | 1419.55 Da |
| Origin | Derived from human gastric protein |
| Research areas | GI protection, tendon repair, muscle healing, neuroprotection |
| Evidence base | Animal models (rodent primary) |
| Human clinical trials | None completed |
| FDA approval | None |
| Storage (lyophilized) | -20°C long-term, 4°C short-term |
Sourcing for research: what to look for
Given its popularity, BPC-157 is one of the most commonly adulterated or mis-identified compounds in the research supply market. A quality CoA should show HPLC purity ≥98%, mass spectrometry confirmation with observed MW matching 1419.55 Da (within ±2 Da), batch-specific documentation, and third-party lab verification from a recognized ISO-certified facility. See our full vendor review and vendor red-flag guide for the complete method.
Frequently asked questions
Is BPC-157 a natural compound?
It is derived from a sequence found in human gastric protein, but the specific 15-amino-acid sequence as used in research is synthetic. It does not occur independently in nature in this form.
Why does so much BPC-157 research come from one group?
A significant portion of the literature originates from the group around Dr. Predrag Sikiric at the University of Zagreb. Independent replication from other labs adds confidence; some tendon and neurological research has come from additional groups, providing partial cross-validation.
How does BPC-157 differ from TB-500?
TB-500 (the research analog of Thymosin Beta-4) is a different peptide with a different mechanism — primarily actin regulation — and somewhat different tissue targets. The two are sometimes studied together in animal models. See our TB-500 vs BPC-157 comparison.
What is the molecular weight of BPC-157?
The theoretical molecular weight is 1419.55 Da. When verifying MS data on a CoA, confirm the observed molecular ion is within roughly ±2 Da of this value.
Bottom line
BPC-157 is one of the more compelling peptides in the current research literature — a relatively coherent proposed mechanism and consistent animal-model findings across several areas. It is also a compound where the gap between animal research and any human application remains entirely unbridged: no human trials, no established human pharmacokinetics, no regulatory approval. A legitimate and interesting subject of investigation — provided all work stays grounded in the actual evidence, not the online extrapolations.